Does the media favor CGEN or SANA?

In the previous week, Sana Biotechnology had 1 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Sana Biotechnology and 4 mentions for Compugen. Sana Biotechnology's average media sentiment score of 0.46 beat Compugen's score of 0.40 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is CGEN or GERN more profitable?

Compugen has a net margin of 47.56% compared to Geron's net margin of -34.17%. Compugen's return on equity of 42.57% beat Geron's return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.56% 42.57% 26.13% Geron -34.17% -24.48% -10.30%

Does the media refer more to CGEN or GERN?

In the previous week, Compugen had 1 more articles in the media than Geron. MarketBeat recorded 4 mentions for Compugen and 3 mentions for Geron. Geron's average media sentiment score of 0.76 beat Compugen's score of 0.40 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Geron 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ANNX or CGEN more profitable?

Compugen has a net margin of 47.56% compared to Annexon's net margin of 0.00%. Compugen's return on equity of 42.57% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Compugen 47.56% 42.57% 26.13%

Does the media prefer ANNX or CGEN?

In the previous week, Compugen had 2 more articles in the media than Annexon. MarketBeat recorded 4 mentions for Compugen and 2 mentions for Annexon. Annexon's average media sentiment score of 1.45 beat Compugen's score of 0.40 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compugen (CGEN) Competitors

$2.00 +0.02 (+1.01%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.04 (+2.00%)

As of 07:56 AM Eastern

Compare

CGEN vs. SANA, GERN, ANNX, LXRX, and CADL

Should you buy Compugen stock or one of its competitors? Compugen's main competitors and comparable companies include Sana Biotechnology (SANA), Geron (GERN), Annexon (ANNX), Lexicon Pharmaceuticals (LXRX), and Candel Therapeutics (CADL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compugen compare to Sana Biotechnology?

Compugen (NASDAQ:CGEN) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

12.2% of Compugen shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compugen presently has a consensus price target of $5.00, suggesting a potential upside of 150.00%. Sana Biotechnology has a consensus price target of $9.33, suggesting a potential upside of 300.57%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Compugen has a beta of 2.78, suggesting that its share price is 178% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

Compugen has a net margin of 47.56% compared to Sana Biotechnology's net margin of 0.00%. Compugen's return on equity of 42.57% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Sana Biotechnology	N/A	-103.02%	-39.16%

Compugen has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

In the previous week, Sana Biotechnology had 1 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Sana Biotechnology and 4 mentions for Compugen. Sana Biotechnology's average media sentiment score of 0.46 beat Compugen's score of 0.40 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Compugen beats Sana Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Compugen compare to Geron?

Compugen (NASDAQ:CGEN) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Compugen presently has a consensus target price of $5.00, suggesting a potential upside of 150.00%. Geron has a consensus target price of $4.00, suggesting a potential upside of 236.13%. Given Geron's higher probable upside, analysts clearly believe Geron is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Compugen had 1 more articles in the media than Geron. MarketBeat recorded 4 mentions for Compugen and 3 mentions for Geron. Geron's average media sentiment score of 0.76 beat Compugen's score of 0.40 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Geron	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.2% of Compugen shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Compugen has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Compugen has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26
Geron	$183.88M	4.16	-$83.50M	-$0.11	N/A

Compugen has a net margin of 47.56% compared to Geron's net margin of -34.17%. Compugen's return on equity of 42.57% beat Geron's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Geron	-34.17%	-24.48%	-10.30%

Summary

Compugen beats Geron on 12 of the 17 factors compared between the two stocks.

How does Compugen compare to Annexon?

Annexon (NASDAQ:ANNX) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Annexon presently has a consensus price target of $15.29, suggesting a potential upside of 316.50%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 150.00%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Compugen has a net margin of 47.56% compared to Annexon's net margin of 0.00%. Compugen's return on equity of 42.57% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Compugen	47.56%	42.57%	26.13%

In the previous week, Compugen had 2 more articles in the media than Annexon. MarketBeat recorded 4 mentions for Compugen and 2 mentions for Annexon. Annexon's average media sentiment score of 1.45 beat Compugen's score of 0.40 indicating that Annexon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annexon	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annexon has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Compugen has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market.

Compugen has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26

12.2% of Compugen shares are owned by institutional investors. 10.3% of Annexon shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Compugen beats Annexon on 11 of the 15 factors compared between the two stocks.

How does Compugen compare to Lexicon Pharmaceuticals?

Compugen (NASDAQ:CGEN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 150.00%. Lexicon Pharmaceuticals has a consensus target price of $5.70, indicating a potential upside of 256.25%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

12.2% of Compugen shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Compugen had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Compugen and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.91 beat Compugen's score of 0.40 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Compugen	Neutral
Lexicon Pharmaceuticals	Positive

Compugen has a net margin of 47.56% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Compugen's return on equity of 42.57% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Compugen has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Compugen has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26
Lexicon Pharmaceuticals	$49.80M	14.30	-$50.34M	-$0.15	N/A

Summary

Compugen beats Lexicon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Compugen compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Compugen has a net margin of 47.56% compared to Candel Therapeutics' net margin of 0.00%. Compugen's return on equity of 42.57% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Compugen	47.56%	42.57%	26.13%

Candel Therapeutics has a beta of -0.32, meaning that its stock price is 132% less volatile than the broader market. Comparatively, Compugen has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Compugen has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Compugen	$72.76M	2.60	$35.34M	$0.38	5.26

In the previous week, Compugen had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for Compugen and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 1.79 beat Compugen's score of 0.40 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Very Positive
Compugen	Neutral

Candel Therapeutics presently has a consensus price target of $20.14, indicating a potential upside of 122.08%. Compugen has a consensus price target of $5.00, indicating a potential upside of 150.00%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe Compugen is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Compugen beats Candel Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$187.21M	$3.85B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.59%
P/E Ratio	5.26	11.31	223.62	21.16
Price / Sales	2.60	1,095.46	547.34	66.59
Price / Cash	5.30	119.79	76.68	52.75
Price / Book	1.83	15.74	10.22	5.92
Net Income	$35.34M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-5.66%	-5.85%	-3.50%	-3.90%
1 Month Performance	-17.01%	-12.91%	-7.78%	-6.42%
1 Year Performance	-2.91%	2.96%	0.79%	-6.02%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.273 of 5 stars	$2.00 +1.0%	$5.00 +150.0%	-5.2%	$187.21M	$72.76M	5.26	75	Analyst Forecast High Trading Volume
SANA Sana Biotechnology	3.3989 of 5 stars	$2.82 -2.3%	$9.33 +231.6%	-47.6%	$842.70M	N/A	N/A	142
GERN Geron	2.0695 of 5 stars	$1.24 +2.1%	$4.00 +223.9%	-4.0%	$793.45M	$183.88M	N/A	258
ANNX Annexon	3.6211 of 5 stars	$4.13 -1.8%	$15.29 +270.6%	+22.3%	$785.81M	N/A	N/A	92
LXRX Lexicon Pharmaceuticals	2.8469 of 5 stars	$1.75 +0.3%	$5.70 +226.6%	+9.6%	$780.91M	$49.80M	N/A	81

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. SANA, GERN, ANNX, LXRX, and CADL

How does Compugen compare to Sana Biotechnology?

Summary

How does Compugen compare to Geron?

Summary

How does Compugen compare to Annexon?

Summary

How does Compugen compare to Lexicon Pharmaceuticals?

Summary

How does Compugen compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. SANA, GERN, ANNX, LXRX, and CADL

How does Compugen compare to Sana Biotechnology?

Do institutionals and insiders have more ownership in CGEN or SANA?

Do analysts rate CGEN or SANA?

Which has more volatility & risk, CGEN or SANA?

Is CGEN or SANA more profitable?

Which has stronger valuation and earnings, CGEN or SANA?

Does the media favor CGEN or SANA?

Summary

How does Compugen compare to Geron?

Do analysts recommend CGEN or GERN?

Does the media refer more to CGEN or GERN?

Do insiders and institutionals hold more shares of CGEN or GERN?

Which has more risk & volatility, CGEN or GERN?

Which has higher valuation and earnings, CGEN or GERN?

Is CGEN or GERN more profitable?

Summary

How does Compugen compare to Annexon?

Do analysts rate ANNX or CGEN?

Is ANNX or CGEN more profitable?

Does the media prefer ANNX or CGEN?

Which has more volatility and risk, ANNX or CGEN?

Which has stronger earnings and valuation, ANNX or CGEN?

Do institutionals & insiders hold more shares of ANNX or CGEN?

Summary

How does Compugen compare to Lexicon Pharmaceuticals?

Do analysts rate CGEN or LXRX?

Do insiders & institutionals believe in CGEN or LXRX?

Does the media favor CGEN or LXRX?

Is CGEN or LXRX more profitable?

Which has more risk & volatility, CGEN or LXRX?

Which has preferable earnings & valuation, CGEN or LXRX?

Summary

How does Compugen compare to Candel Therapeutics?

Is CADL or CGEN more profitable?

Which has more volatility & risk, CADL or CGEN?

Do insiders and institutionals have more ownership in CADL or CGEN?

Which has higher earnings and valuation, CADL or CGEN?

Does the media prefer CADL or CGEN?

Do analysts rate CADL or CGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools